WO2002032880A1 - Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparación y su aplicación como medicamentos - Google Patents
Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparación y su aplicación como medicamentos Download PDFInfo
- Publication number
- WO2002032880A1 WO2002032880A1 PCT/ES2001/000378 ES0100378W WO0232880A1 WO 2002032880 A1 WO2002032880 A1 WO 2002032880A1 ES 0100378 W ES0100378 W ES 0100378W WO 0232880 A1 WO0232880 A1 WO 0232880A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyano
- radical
- piperazinyl
- general formula
- pyridylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to new cyanoaryl (or cyanoheteroaryl) -carbonyl-piperazinyl-pyrimidines, of general formula (I), as well as to their physiologically acceptable salts, to the procedures for their preparation, to their application as medicaments in human therapy and / or veterinary and pharmaceutical compositions containing them.
- the new compounds object of the present invention can be used in the pharmaceutical industry as intermediates and for the preparation of medicaments.
- acyl-piperazinyl-pyrimidines among which are the compounds of general formula (I), such as products with sedative, anticonvulsant, hypnotic and general anesthetic activity.
- Said patent describes derivatives of general formula (I) in which R 2 represents, among others, an aryl radical and a heteroaryl radical.
- aryl represents a phenyl radical unsubstituted or substituted by 1, 2 or 3 identical or different substituents such as fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl or methoxy.
- heteroaryl represents a substituted or unsubstituted heteroaromatic ring of 5 or 6 members or substituted or unsubstituted fused heteroaromatic systems of 9 to 10 members consisting of 1 or 2 heteroatoms such as nitrogen, oxygen or sulfur, the substituents being groups such as fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl or methoxy.
- substituents being groups such as fluorine, chlorine, bromine, amino, acetamido, nitro, methyl, trifluoromethyl or methoxy.
- the present invention provides new compounds with sedative, anticonvulsant, analgesic, muscle relaxant, antitussive, anxiolytic, antipsychotic, antidepressant, cerebral antiischemic, antimlgrainous, sleep disorders, neurodegenerative diseases, cognitive disorders and disease Alzheimer's, hypnotic or general anesthetic, in mammals, including man.
- the new compounds of the invention are capable of causing conscious sedation, of acting as hypnotic agents and agents capable of inducing or maintaining general anesthesia, according to the dose and route of administration.
- R ⁇ represents an alkoxy radical and R 2 represents a cyanoaryl radical or a cyanoheteroaryl radical.
- alkoxy represents an OR 3 radical, wherein
- R 3 is C 1 -C 4 alkyl (ie, an alkyl radical derived from a saturated, straight or branched chain hydrocarbon of 1 to 4 carbon atoms), such as methoxy, ethoxy, propoxy, isopropoxy, butoxy , sec-butoxy or ferc-butoxy.
- cyanoaryl represents a phenyl radical substituted at least by a cyano radical (-C ⁇ N).
- cyanoheteroaryl represents a radical of a 5- or 6-membered heteroaromatic ring or of substituted or unsubstituted fused heteroaromatic systems of 9 to 10 members consisting of 1 or 2 heteroatoms such as nitrogen, oxygen or sulfur, all substituted, as minimum, by a cyano radical (-C ⁇ N), such as, for example, 3-cyano-2-furyl, 3-cyano-2-thienyl, 5-cyano-2-thienyl, 3- cyano-2-pyrrolyl, 3 -cyano-2-pyridyl, 2-cyano-3-pyridyl, 2-cyano-4-pyridyl, 3-cyano-2- indolyl, 2-cyano-3-indolyl, 3-cyano-2-benzo [b] thienyl or 2-cyano-3-benzo [b] thienyl or
- the present invention also relates to the physiologically acceptable salts of the compounds of general formula (I), in particular the addition salts of mineral acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acid and with organic acids such as p-toluenesulfonic acid or methanesulfonic acid.
- mineral acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acid
- organic acids such as p-toluenesulfonic acid or methanesulfonic acid.
- the compounds of the general formula (I) can be prepared by reacting the amine of the general formula (II) in which R- has the meaning indicated above with a carboxylic acid of the general formula R 2 COOH (III), in which R 2 has the meaning indicated above, either with a salt of this same acid or also with a reactive derivative R 2 COX (IV), (Scheme 1).
- salts include alkali metal salts such as sodium salt and potassium salt, alkaline earth salts such as calcium salt and magnesium salt, ammonium salt, and salts of organic bases such as triethylamine, trimethylamine, pyridine and picoline.
- Examples of reactive derivatives of the general formula R 2 COX (IV) include those in which X is a halogen atom preferably a chlorine atom or a bromine atom, an azido group (-N 3 ), a 1-imidazolyl group, a 0-CO-R 4 group , where R 4 can be an alkyl radical of 1 to 6 carbon atoms or aryl, optionally substituted by one or more halogen atoms, or an OR 5 group where R 5 represents an aromatic group of one or two rings substituted by one or several halogen atoms or nitro radicals, with 4-nitrophenyl, 2,4-dinitrophenyl, pentachlorophenyl, pentafluorophenyl, 1-benzotriazolyl or N-succinimide groups being preferred.
- X is a halogen atom preferably a chlorine atom or a bromine atom, an azido group (-N 3 ), a 1-imidazolyl group,
- the compounds of the general formula (I) can be prepared directly by reacting the amine (II) with the carboxylic acid of the general formula R 2 COOH (III), preferring in this case that the reaction proceed in the presence of carbonyl group activation reagents such as N, N'-dicyclohexylcarbodimide, N, N'-diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-1-ethylcarbodiimide.
- This reaction can also be carried out using the carbodiimides mentioned in the presence of 1- benzotriazole or N-hydroxysuccinimide.
- the acids of the general formula (III) and the amine of the general formula (II) also react directly in the presence of N, N'-carbonyldiimidazole or of the propanophosphonic acid anhydride.
- the reaction is carried out in an organic solvent, such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide, acetonitrile or dimethylformamide or any other suitable solvent.
- organic solvent such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide, acetonitrile or dimethylformamide or any other suitable solvent.
- the reaction can be carried out in the presence of a mineral or organic base such as an aliphatic amine, preferably triethylamine or N-methylmorpholine and stirred
- the reaction is carried out in an organic solvent, such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide, acetonltrile, dimethylformamide or any other suitable solvent.
- organic solvent such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide, acetonltrile, dimethylformamide or any other suitable solvent.
- the reaction can be carried out in the presence of a mineral or organic base such as an aliphatic amine, preferably triethylamine or N-methylmorpholine and
- the oxime of the general formula (Vil) in which R has the meaning indicated above is obtained by reacting the aldehyde of the general formula (VI) with hydroxylamine or a hydroxylamine salt.
- the reaction is carried out in an organic solvent such as ethanol, or a mixture of ethanol and water or any other suitable solvent.
- the reaction can be carried out in the presence of a base such as sodium hydroxide, sodium carbonate or sodium acetate or an aliphatic amine, preferably pyridine, triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent for a period between one hour and twenty four hours.
- the reaction with the anhydride (VIII) is carried out in an organic solvent, such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide, dimethylformamide, acetonitrile or any other suitable solvent.
- the reaction can be carried out in the presence of a mineral or organic base such as an aliphatic amine, preferably triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent for a period between ten minutes.
- reaction with the acid of general formula (IX) is carried out in the presence of carbonyl group activation reagents such as N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-1 - ethylcarbodiimide.
- carbonyl group activation reagents such as N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-1 - ethylcarbodiimide.
- This reaction can also be carried out using the carbodiimides mentioned in the presence of 1-benzotriazole or N-hydroxysuccinimide or by reaction of the acid (IX) with reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride .
- reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride .
- the acid of the general formula (IX) and the amine of the general formula (II) also react directly in the presence of N, N'-carbonyldiimidazole or of the propanophosphonic acid anhydride.
- the reaction is carried out in an organic solvent such as methylene chloride, chloroform, pyridine or any other suitable solvent.
- the reaction is carried out in the presence of a base such as sodium hydroxide, sodium carbonate or sodium acetate, an aliphatic amine, preferably pyridine, triethylamine or N-methylmorphol, and stirred at a temperature between room temperature and the boiling point of the solvent during a period between one hour and twenty four hours.
- a base such as sodium hydroxide, sodium carbonate or sodium acetate, an aliphatic amine, preferably pyridine, triethylamine or N-methylmorphol
- Activation of the carbonyl group of the acid of the general formula (X) is carried out by reacting (X) with reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride.
- reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride.
- the reaction of the acid (X) with ammonia can also be carried out in the presence of carbonyl group activation reagents such as N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-1-ethylcarbodiimide. This reaction can also be performed.
- the acid of general formula (X) and ammonia also react directly in the presence of N, N'-carbonyldiimidazole.
- the reaction is carried out in an organic solvent such as methylene chloride, chloroform, pyridine or any other suitable solvent.
- the reaction is carried out in the presence of a base such as sodium hydroxide, sodium carbonate or sodium acetate, an aliphatic amine, preferably pyridine, triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent. for a period between one hour and twenty four hours.
- the reaction is carried out in an organic solvent such as dimethylformamide, methylene chloride, toluene and in the presence of a base such as triethylamine or pyridine at a temperature between 0 ° C and the boiling temperature of the solvent for a period between one hour and twenty four hours.
- organic solvent such as dimethylformamide, methylene chloride, toluene
- a base such as triethylamine or pyridine
- the reaction is carried out by treating the acid of general formula (XII) with carbonyl group activation reagents and subsequent treatment with the amine of general formula (II).
- Activation of the carbonyl group of the acid of the general formula (XII) is carried out by treatment with reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride.
- reaction of the acid (XII) with the amine of general formula (II) can also be carried out in the presence of carbonyl group activation reagents such as N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide or 3- (3-dimethylamino ) propyl-1-ethylcarbodiimide.
- carbonyl group activation reagents such as N, N'-dicyclohexylcarbodiimide, N, N'-diisopropylcarbodiimide or 3- (3-dimethylamino ) propyl-1-ethylcarbodiimide.
- This reaction can also be carried out using the carbodiimides mentioned in the presence of 1-benzotriazole or N-hydroxysuccinimide.
- the acid of the general formula (XII) and the amine (II) also react directly in the presence of N, N'-carbonyldi
- the reaction is carried out in an organic solvent such as methylene chloride, chloroform or pyridine or any other suitable solvent.
- the reaction is carried out in the presence of a base such as sodium hydroxide, sodium carbonate, sodium acetate or an aliphatic amine, preferably pyridine, triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent. for a period between one hour and twenty four hours.
- a base such as sodium hydroxide, sodium carbonate, sodium acetate or an aliphatic amine, preferably pyridine, triethylamine or N-methylmorpholine
- the hydrolysis of the amide ester group of the general formula (XIII) in which R ⁇ R 6 and Y has the meaning indicated above leads to the formation of the acid of the general formula (XIV) where R, and Y has the meaning indicated above .
- the hydrolysis is carried out by conventional methods such as saponification with sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate or potassium carbonate or by hydrolysis in an acid medium such as hydrochloric acid.
- the reaction is carried out in a solvent such as methanol, ethanol, water, tetrahydrofuran or a mixture thereof at a temperature between room temperature and the boiling temperature of the solution for a period between one hour and twenty four hours. .
- the amide of the general formula (XV) in which R, and Y have the meaning indicated above is obtained by reacting the acid of the general formula (XIV) with carbonyl group activation reagents and subsequent treatment with ammonia. Activation of the carbonyl group of the acid of the general formula (XIV) is carried out with reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride.
- reagents such as thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloroformate or methanesulfonyl chloride.
- reaction of acid (XIV) with ammonia can also be carried out in the presence of activation reagents of carbonyl groups such as N, N'-dicyclohexylcarbodiimide, N.N'-diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-1-ethylcarbodiimide.
- activation reagents of carbonyl groups such as N, N'-dicyclohexylcarbodiimide, N.N'-diisopropylcarbodiimide or 3- (3-dimethylamino) propyl-1-ethylcarbodiimide.
- This reaction can also be carried out using the carbodiimides mentioned in the presence of 1-benzotriazole or N-hydroxysuccinimide.
- the acid of general formula (XIV) and ammonia also react directly in the presence of N, N'-carbonyldiimidazole.
- the reaction is carried out in an organic solvent such as methylene chloride, chloroform or pyridine or any other suitable solvent.
- the reaction is carried out in the presence of a base such as sodium hydroxide, sodium carbonate, sodium acetate or an aliphatic amine, preferably pyridine, triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent. for a period between one hour and twenty four hours.
- a base such as sodium hydroxide, sodium carbonate, sodium acetate or an aliphatic amine, preferably pyridine, triethylamine or N-methylmorpholine
- the reaction is carried out in an organic solvent such as DMF, methylene chloride or toluene and in the presence of a base such as triethylamine or pyridine at a temperature between 0 ° C and the boiling temperature of the solvent for a period between one hour and twenty four hours.
- organic solvent such as DMF, methylene chloride or toluene
- a base such as triethylamine or pyridine
- METHOD F The new derivatives of general formula (I), in which R ⁇ and R 2 have the meaning indicated above, can be prepared by reacting the chloropyrimidine derivative of general formula (XVIII), where R., has the meaning indicated above, with a piperazine derivative of the general formula (XIX), where R 2 has the meaning indicated above, according to the method represented in scheme 6:
- the reaction is carried out in an organic solvent, such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide , dimethylformamide or acetonitrile, a protic polar solvent such as methanol, ethanol, sopropanol or n-butanol or any other suitable solvent to effect an aromatic nucleophilic substitution reaction.
- an organic solvent such as a chlorinated organic hydrocarbon such as dichloromethane or chloroform, a linear or cyclic ether such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, an aprotic polar solvent such as pyridine, dimethyl sulfoxide , dimethylformamide or acetonitrile, a protic polar solvent such
- the reaction can be carried out in the presence of a mineral base such as sodium carbonate or potassium or organic carbonate such as an aliphatic amine, preferably triethylamine or N-methylmorpholine and stirred at a temperature between room temperature and the boiling point of the solvent. for a period between ten minutes and twenty four hours, being the period between thirty minutes and five hours preferred conditions.
- a mineral base such as sodium carbonate or potassium or organic carbonate such as an aliphatic amine, preferably triethylamine or N-methylmorpholine
- METHOD G The salts of the compounds of general formula (I) are prepared by reaction with a mineral acid such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acid or an organic acid such as p-toluenesulfonic acid or methanesulfonic acid in the within an appropriate solvent such as methanol, ethanol, ethyl ether, ethyl acetate or acetone, the corresponding salts being obtained by usual precipitation or crystallization techniques.
- a mineral acid such as hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acid or an organic acid such as p-toluenesulfonic acid or methanesulfonic acid
- an appropriate solvent such as methanol, ethanol, ethyl ether, ethyl acetate or acetone
- Example 3 Preparation of 2- [4- (2-Cyanobenzoyl) -1-piperazinyl] -4-ethoxypyrimidine. To a solution of 2.08 g (10 mmol) of 4-ethoxy-2- (1-piperazinyl) pyrimidine and 5 mL of triethylamine in 60 mL of dry THF is added 2.15 g (10 mmol) of 3- bromoftalide and kept under stirring at room temperature for 4 hours.
- the solvent is evaporated under reduced pressure to obtain the acetylated oxime.
- the acetylated oxime is dissolved in 20 mL of acetonitrile and excess K 2 C0 3 is added and left under stirring at room temperature for 78 hours.
- the solid is filtered, the solvent is removed under reduced pressure, diluted in CH 2 CI 2 and washed with H 2 0.
- Example 15 Preparation of 2- [4- (3-cyano-2-pyridylcarbonyl) -1-piperazinyl] -4-ethoxypyrimidine.
- Example 19- Preparation of 2- [4- (2-Cyano-3-pyridylcarbonyl) -1-p'perazinyl] -4-ethoxypyrimidine.
- To a solution of 1.33 g (7.45 mmol) of 2-methoxycarbonylnicotinic acid in 15 mL of ice-cold DMF is added 1.20 g (7.45 mmol) of N, N'-carbonyldiimidazole and Let it stir for 40 minutes.
- To the reaction mixture is added 1.53 g (7.45 mmol) of 4-ethoxy-2- (1-piperazinyl) pyrimidine and left at room temperature for two hours.
- the resulting crude is suspended in 30 mL of methylene chloride and 0.45 mL (3.3 mmol) of triethylamine is added and brought to 0 ° C and 0.3 g (2.76 mmol) of ethyl chloroformate keeping the solution at this temperature for 30 minutes.
- the resulting mixture is bubbled with NH 3 (gas) for 1 minute and the temperature is maintained at 0 ° C for 2 hours.
- Table 1 describes some illustrative compounds of the invention, indicating their method of obtaining, melting point and spectroscopic characteristics thereof.
- the anesthetic activity was determined after intravenous (i.v.) administration of the product under study at three different doses (15, 10, and 5 mg / kg) in the caudal vein of the mouse. The percentage of anesthetized animals was counted and the duration of anesthesia was averaged. The mice were considered anesthetized by losing all 3 reflexes: position reflex, response response to painful stimulation (pinching in the tail) and palpebral reflex.
- a saline solution of the products under study was perfused at a concentration and rate of 5 mg / ml / minute, by means of an infusion pump through a cannula inserted into a vein of a front leg.
- the iv infusion was interrupted when the animal was completely anesthetized (loss of motor coordination, sedation, loss of response a painful stimulus - prick in the fingers of the anterior leg - and loss of the eyelid reflex) and the anesthetic dose was determined (Table 3).
- mice Convulsions by cardiazole
- Sedative activity has been studied by observing the behavior of animals after administration of a dose of 80 mg / kg intraperitoneally (i.p.). This observation was made at different times, which allows to know the sedative effect and its duration. The results obtained show that the products under study had a sedative effect, being in some cases comparable to that of zolpidem and in other cases of longer duration (Table 6).
- mice 80 mg / kg, i.p.
- the relaxing muscle activity of the products object of the invention has been studied, assessing its effect on the body tone and abdominal tone of the rats, following the method described by S. IRWIN (Gordon Res.Conf. On Medicinal Chem., 1959 , p.133). Rats received the products under study at the dose of 80 mg / kg, via ip, and at different times after administration (1/2, 1, 2, 3, 4 and 5 hours) body tone and abdominal tone were evaluated assessing muscle tension compared to control animals. The results reported in Table 7 show that many products have a remarkable muscle relaxant activity, this effect being longer than propofol, taken as a reference product.
- Propofol 100 100 70 0 0 0 0
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001293877A AU2001293877B2 (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
DE60131873T DE60131873T2 (de) | 2000-10-20 | 2001-10-10 | Neue derivate von cyanoaryl-(oder cyanoheteroaryl-) carbonylpiperazinylpyrimidinen, ihre herstellung und anwendung als medizin |
PL01361033A PL361033A1 (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
EP01974344A EP1327630B1 (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
CA002426097A CA2426097A1 (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
JP2002536263A JP2004511550A (ja) | 2000-10-20 | 2001-10-10 | シアノ−アリール(またはシアノヘテロアリール)−カルボニル−ピペラジニル−ピリミジン類の新規誘導体、その製法および医薬としての応用 |
NZ525246A NZ525246A (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
KR10-2003-7005303A KR20030037687A (ko) | 2000-10-20 | 2001-10-10 | 시아노-아릴(또는 시아노헤테로아릴)-카보닐-피페라지닐의신규한 유도체, 이들의 제조 및 약물로서 이들의 용도 |
IL15525901A IL155259A0 (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl) or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
MXPA03003348A MXPA03003348A (es) | 2000-10-20 | 2001-10-10 | Nuevos derivados de cianoaril (o-cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
US10/312,195 US7300937B2 (en) | 2000-10-20 | 2001-10-10 | Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
BR0114999-7A BR0114999A (pt) | 2000-10-20 | 2001-10-10 | Derivado de cianoarila (ou cianoheteroarila) - carbonil - piperazinil-pirimidina, procedimento para a preparação de sais fisiologicamente aceitáveis do referido derivado, composição farmacêutica e uso do derivado |
AU9387701A AU9387701A (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
HU0302901A HUP0302901A3 (en) | 2000-10-20 | 2001-10-10 | New derivatives of cyano-aryl (or cyanoheteroaryl)carbonylpiperazinyl-pyrimidines, their preparation, and pharmaceutical compositions containing them |
NO20031771A NO20031771L (no) | 2000-10-20 | 2003-04-16 | Nye derivater av cyanoaryl(eller cyanoheteroaryl)-karbonyl- piperazinylpyrimidiner, deres fremstilling og anvendelse som medikament |
HK04103417A HK1060358A1 (en) | 2000-10-20 | 2004-05-14 | Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200002532A ES2167276B1 (es) | 2000-10-20 | 2000-10-20 | Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
ESP200002532 | 2000-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002032880A1 true WO2002032880A1 (es) | 2002-04-25 |
Family
ID=8495344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2001/000378 WO2002032880A1 (es) | 2000-10-20 | 2001-10-10 | Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparación y su aplicación como medicamentos |
Country Status (25)
Country | Link |
---|---|
US (1) | US7300937B2 (es) |
EP (1) | EP1327630B1 (es) |
JP (1) | JP2004511550A (es) |
KR (1) | KR20030037687A (es) |
CN (1) | CN1221536C (es) |
AR (1) | AR030885A1 (es) |
AT (1) | ATE380795T1 (es) |
AU (2) | AU2001293877B2 (es) |
BR (1) | BR0114999A (es) |
CA (1) | CA2426097A1 (es) |
CZ (1) | CZ20031116A3 (es) |
DE (1) | DE60131873T2 (es) |
ES (2) | ES2167276B1 (es) |
HK (1) | HK1060358A1 (es) |
HU (1) | HUP0302901A3 (es) |
IL (1) | IL155259A0 (es) |
MX (1) | MXPA03003348A (es) |
NO (1) | NO20031771L (es) |
NZ (1) | NZ525246A (es) |
PL (1) | PL361033A1 (es) |
PT (1) | PT1327630E (es) |
RU (1) | RU2259358C2 (es) |
TW (1) | TWI220144B (es) |
WO (1) | WO2002032880A1 (es) |
ZA (1) | ZA200302452B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003212335B8 (en) * | 2002-03-13 | 2009-04-23 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
CN103360343B (zh) * | 2012-03-30 | 2017-04-19 | 凯惠药业(上海)有限公司 | 一种哌嗪酰胺类化合物的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0115713A1 (fr) * | 1982-11-09 | 1984-08-15 | Sanofi S.A. | (Pipérazinyl-1)-2 pyrimidines, leurs sels, procédé pour leur préparation et compositions pharmaceutiques en contenant |
US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
EP0382637A1 (fr) * | 1989-02-09 | 1990-08-16 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de pyrimidinyl-piperazinyl-alkyl azolès avec activité anxiolytique et/ou tranquillisante |
JPH04202185A (ja) * | 1990-11-30 | 1992-07-22 | Terumo Corp | ピペラジン誘導体及びこれを含有する医薬製剤 |
EP0497659A1 (fr) * | 1991-01-28 | 1992-08-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments |
ES2034909A6 (es) * | 1989-11-22 | 1993-04-01 | Esteve Labor Dr | Metodo para la obtencion de derivados de 1h-azol-(w-(4-(2-pirimidinil)-1-piperazinil)-alquilo. |
WO1999005121A1 (es) * | 1997-07-21 | 1999-02-04 | Laboratorios Del Dr. Esteve, S.A. | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668687A (en) * | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
-
2000
- 2000-10-20 ES ES200002532A patent/ES2167276B1/es not_active Expired - Fee Related
-
2001
- 2001-10-10 CN CNB018176291A patent/CN1221536C/zh not_active Expired - Fee Related
- 2001-10-10 JP JP2002536263A patent/JP2004511550A/ja active Pending
- 2001-10-10 US US10/312,195 patent/US7300937B2/en not_active Expired - Fee Related
- 2001-10-10 PT PT01974344T patent/PT1327630E/pt unknown
- 2001-10-10 BR BR0114999-7A patent/BR0114999A/pt not_active IP Right Cessation
- 2001-10-10 AU AU2001293877A patent/AU2001293877B2/en not_active Ceased
- 2001-10-10 EP EP01974344A patent/EP1327630B1/en not_active Expired - Lifetime
- 2001-10-10 RU RU2003114437/04A patent/RU2259358C2/ru not_active IP Right Cessation
- 2001-10-10 NZ NZ525246A patent/NZ525246A/en unknown
- 2001-10-10 AU AU9387701A patent/AU9387701A/xx active Pending
- 2001-10-10 CA CA002426097A patent/CA2426097A1/en not_active Abandoned
- 2001-10-10 CZ CZ20031116A patent/CZ20031116A3/cs unknown
- 2001-10-10 ES ES01974344T patent/ES2296806T3/es not_active Expired - Lifetime
- 2001-10-10 MX MXPA03003348A patent/MXPA03003348A/es active IP Right Grant
- 2001-10-10 PL PL01361033A patent/PL361033A1/xx not_active Application Discontinuation
- 2001-10-10 DE DE60131873T patent/DE60131873T2/de not_active Expired - Lifetime
- 2001-10-10 AT AT01974344T patent/ATE380795T1/de not_active IP Right Cessation
- 2001-10-10 WO PCT/ES2001/000378 patent/WO2002032880A1/es active IP Right Grant
- 2001-10-10 KR KR10-2003-7005303A patent/KR20030037687A/ko active IP Right Grant
- 2001-10-10 IL IL15525901A patent/IL155259A0/xx unknown
- 2001-10-10 HU HU0302901A patent/HUP0302901A3/hu unknown
- 2001-10-12 AR ARP010104819A patent/AR030885A1/es unknown
- 2001-10-17 TW TW090125627A patent/TWI220144B/zh not_active IP Right Cessation
-
2003
- 2003-03-28 ZA ZA200302452A patent/ZA200302452B/en unknown
- 2003-04-16 NO NO20031771A patent/NO20031771L/no not_active Application Discontinuation
-
2004
- 2004-05-14 HK HK04103417A patent/HK1060358A1/xx not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0115713A1 (fr) * | 1982-11-09 | 1984-08-15 | Sanofi S.A. | (Pipérazinyl-1)-2 pyrimidines, leurs sels, procédé pour leur préparation et compositions pharmaceutiques en contenant |
US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
EP0382637A1 (fr) * | 1989-02-09 | 1990-08-16 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de pyrimidinyl-piperazinyl-alkyl azolès avec activité anxiolytique et/ou tranquillisante |
ES2034909A6 (es) * | 1989-11-22 | 1993-04-01 | Esteve Labor Dr | Metodo para la obtencion de derivados de 1h-azol-(w-(4-(2-pirimidinil)-1-piperazinil)-alquilo. |
JPH04202185A (ja) * | 1990-11-30 | 1992-07-22 | Terumo Corp | ピペラジン誘導体及びこれを含有する医薬製剤 |
EP0497659A1 (fr) * | 1991-01-28 | 1992-08-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments |
WO1999005121A1 (es) * | 1997-07-21 | 1999-02-04 | Laboratorios Del Dr. Esteve, S.A. | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos |
Non-Patent Citations (1)
Title |
---|
DATABASE HACPLUS [online] XP002950672, accession no. STN Database accession no. 1993:101988 * |
Also Published As
Publication number | Publication date |
---|---|
ES2167276A1 (es) | 2002-05-01 |
IL155259A0 (en) | 2003-11-23 |
PT1327630E (pt) | 2008-03-05 |
ZA200302452B (en) | 2004-03-29 |
NO20031771D0 (no) | 2003-04-16 |
HK1060358A1 (en) | 2004-08-06 |
HUP0302901A3 (en) | 2004-04-28 |
MXPA03003348A (es) | 2003-06-19 |
ATE380795T1 (de) | 2007-12-15 |
ES2167276B1 (es) | 2003-04-01 |
NO20031771L (no) | 2003-06-06 |
EP1327630A1 (en) | 2003-07-16 |
DE60131873T2 (de) | 2008-12-04 |
ES2296806T3 (es) | 2008-05-01 |
CN1221536C (zh) | 2005-10-05 |
RU2259358C2 (ru) | 2005-08-27 |
HUP0302901A2 (hu) | 2004-03-01 |
CA2426097A1 (en) | 2003-04-16 |
DE60131873D1 (de) | 2008-01-24 |
NZ525246A (en) | 2004-11-26 |
BR0114999A (pt) | 2004-02-03 |
TWI220144B (en) | 2004-08-11 |
US20040048872A1 (en) | 2004-03-11 |
AU2001293877B2 (en) | 2007-01-04 |
CZ20031116A3 (cs) | 2003-10-15 |
EP1327630B1 (en) | 2007-12-12 |
JP2004511550A (ja) | 2004-04-15 |
AU9387701A (en) | 2002-04-29 |
CN1469866A (zh) | 2004-01-21 |
US7300937B2 (en) | 2007-11-27 |
KR20030037687A (ko) | 2003-05-14 |
AR030885A1 (es) | 2003-09-03 |
PL361033A1 (en) | 2004-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2216297T3 (es) | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. | |
ES2375134T3 (es) | Derivados de piperazina y su uso como agentes terapéuticos. | |
Alagarsamy et al. | Synthesis and pharmacological investigation of novel 4-benzyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents | |
CA2683557C (en) | Inhibitors of histone deacetylase | |
ES2729424T3 (es) | Inhibidores de Rho cinasa | |
KR101264444B1 (ko) | 록사핀 유사체 및 이것의 사용 방법 | |
AU722480B2 (en) | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | |
ES2382806T3 (es) | Compuesto ácido ciclohexanocarboxílico | |
US5872119A (en) | 2-Naphthamide derivatives and their therapeutic applications | |
KR100686757B1 (ko) | 2,4-치환된 인돌 및 그의 5-ht6 조절제로서 용도 | |
CN102438989B (zh) | 噁唑酮和吡咯烷酮取代的芳基酰胺 | |
Alagarsamy et al. | Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents | |
JPH0367071B2 (es) | ||
US11827640B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | |
CA1340205C (en) | Alkylene diamines | |
ES2239592T3 (es) | Derivados de carbamoil tetrahidropirina. | |
ES2309822T3 (es) | Derivado de amida del acido pirrolopiridina-2-carboxilico util como inhibidor de la glucogeno-fosforilasa. | |
EP1886996A1 (en) | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | |
ES2210384T3 (es) | Derivados de la pirimidina. | |
ES2296806T3 (es) | Nuevos derivados de cianoril (o cianoheteroaril)-carbonil-piperazini l-pirimidinas, su preparacion y su aplicacion como medeicamentos. | |
US3726880A (en) | Organic amides and methods for their production | |
JP2003231633A (ja) | 医薬組成物 | |
JPH0114236B2 (es) | ||
ES2285544T3 (es) | Derivados de pirrolo-pirazina utiles como moduladores de cb1. | |
JPH0687812A (ja) | 生理活性を有するオキシム類およびそれらのo−アシル誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10312195 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/02452 Country of ref document: ZA Ref document number: 200302452 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 374/KOLNP/2003 Country of ref document: IN Ref document number: 00374/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001293877 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 155259 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001974344 Country of ref document: EP Ref document number: 525246 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/003348 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2426097 Country of ref document: CA Ref document number: 1020037005303 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-1116 Country of ref document: CZ Ref document number: 018176291 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002536263 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037005303 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: RU Ref document number: RU A Ref document number: 2003114437 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2001974344 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-1116 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 525246 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525246 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001974344 Country of ref document: EP |